Phase II
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA)
Iovance Biotherapeutics, Inc.
PR-M07-19-NI-016Jul 08, 2019
Market Expansion
Iovance Announces Plans to Build Cell Therapy Production Plant in U.S.
Emilie Branch
Pharma's Almanac
PAO-M06-19-NI-005Jun 13, 2019
New Facility
Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products
Nice Insight
PR-M05-19-NI-082May 30, 2019